Literature DB >> 28962205

Successful treatment of acute renal infarction arising from left atrial myxoma and atrial fibrillation: A case report.

Lei Ji1, Junli Gong1, Feng Liu2, Yixuan Wang2, Dan Jiao3, Ziyuan Ni2, Guanjie Zhao2, Yingying Liu2.   

Abstract

Acute renal infarction (ARI) is an uncommon disease and delayed diagnosis or misdiagnosis often leads to rapid deterioration of the patient. As patients with atrial fibrillation and left atrial myxomas are at risk of developing ARI due to cardiogenic thromboembolism, it is pivotal for clinicians to make a correct diagnosis and start a timely treatment. The present study reported on the case of a 68-year-old man who suffered from ARI secondary to thromboembolism associated with atrial fibrillation and left atrial myxomas. His renal function deteriorated rapidly after the onset of the attack. He was treated with anti-coagulant agents with excellent results. Classical anti-coagulation therapy remains to be the effective and safe treatment of ARI.

Entities:  

Keywords:  anti-coagulant agents; infarction; kidney

Year:  2017        PMID: 28962205      PMCID: PMC5609269          DOI: 10.3892/etm.2017.4806

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  14 in total

Review 1.  Cardiac tumours: diagnosis and management.

Authors:  Jagdish Butany; Vidhya Nair; Ather Naseemuddin; Girish M Nair; Charles Catton; Teri Yau
Journal:  Lancet Oncol       Date:  2005-04       Impact factor: 41.316

2.  Conservative management of renal artery embolus.

Authors:  J D Moyer; C N Rao; W C Widrich; C A Olsson
Journal:  J Urol       Date:  1973-02       Impact factor: 7.450

3.  A retrospective study of short- and long-term effects on renal function after acute renal infarction.

Authors:  Eun Jin Bae; Kyungo Hwang; Ha Nee Jang; Min Jeong Kim; Dae-Hong Jeon; Hyun-Jung Kim; Hyun Seop Cho; Se-Ho Chang; Dong Jun Park
Journal:  Ren Fail       Date:  2014-08-12       Impact factor: 2.606

4.  A case series of acute renal infarction at a single center in Japan.

Authors:  Tasuku Nagasawa; Ken Matsuda; Yoichi Takeuchi; Hirotaka Fukami; Hiroyuki Sato; Ayako Saito; Yoichiro Chikamatsu; Yasumichi Kinoshita
Journal:  Clin Exp Nephrol       Date:  2015-09-16       Impact factor: 2.801

5.  The clinical spectrum of acute renal infarction.

Authors:  Ze'ev Korzets; Eleanora Plotkin; Jacques Bernheim; Rivka Zissin
Journal:  Isr Med Assoc J       Date:  2002-10       Impact factor: 0.892

6.  Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.

Authors:  Bram J Geller; Robert P Giugliano; Eugene Braunwald; Sabina A Murphy; James J Hanyok; Jianqing Jin; Michele Mercuri; Elliott M Antman; Christian T Ruff
Journal:  Am Heart J       Date:  2015-07-02       Impact factor: 4.749

7.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

8.  Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.

Authors:  Juan Jesús Carrero; Marie Evans; Karolina Szummer; Jonas Spaak; Lars Lindhagen; Robert Edfors; Peter Stenvinkel; Stefan H Jacobson; Tomas Jernberg
Journal:  JAMA       Date:  2014-03-05       Impact factor: 56.272

9.  Current status of anticoagulant therapy.

Authors:  D Deykin
Journal:  Am J Med       Date:  1982-04       Impact factor: 4.965

10.  Clinical Characteristics and Outcomes of Renal Infarction.

Authors:  Yun Kuy Oh; Chul Woo Yang; Yong-Lim Kim; Shin-Wook Kang; Cheol Whee Park; Yon Su Kim; Eun Young Lee; Byoung Geun Han; Sang Ho Lee; Su-Hyun Kim; Hajeong Lee; Chun Soo Lim
Journal:  Am J Kidney Dis       Date:  2015-11-04       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.